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BACKGROUND
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
variants threatens progress toward control of the coronavirus disease 2019 
(Covid-19) pandemic. In a phase 1–2 trial involving healthy adults, the NVX-
CoV2373 nanoparticle vaccine had an acceptable safety profile and was associated 
with strong neutralizing-antibody and antigen-specific polyfunctional CD4+ T-cell 
responses. Evaluation of vaccine efficacy was needed in a setting of ongoing SARS-
CoV-2 transmission.
METHODS
In this phase 2a–b trial in South Africa, we randomly assigned human immuno-
deficiency virus (HIV)–negative adults between the ages of 18 and 84 years or 
medically stable HIV-positive participants between the ages of 18 and 64 years in 
a 1:1 ratio to receive two doses of either the NVX-CoV2373 vaccine (5 μg of recom-
binant spike protein with 50 μg of Matrix-M1 adjuvant) or placebo. The primary 
end points were safety and vaccine efficacy against laboratory-confirmed symp-
tomatic Covid-19 at 7 days or more after the second dose among participants 
without previous SARS-CoV-2 infection.
RESULTS
Of 6324 participants who underwent screening, 4387 received at least one injection 
of vaccine or placebo. Approximately 30% of the participants were seropositive for 
SARS-CoV-2 at baseline. Among 2684 baseline seronegative participants (94% HIV-
negative and 6% HIV-positive), predominantly mild-to-moderate Covid-19 devel-
oped in 15 participants in the vaccine group and in 29 in the placebo group (vac-
cine efficacy, 49.4%; 95% confidence interval [CI], 6.1 to 72.8). Vaccine efficacy 
among HIV-negative participants was 60.1% (95% CI, 19.9 to 80.1). Of 41 se-
quenced isolates, 38 (92.7%) were the B.1.351 variant. Post hoc vaccine efficacy 
against B.1.351 was 51.0% (95% CI, −0.6 to 76.2) among the HIV-negative partici-
pants. Preliminary local and systemic reactogenicity events were more common in 
the vaccine group; serious adverse events were rare in both groups.
CONCLUSIONS
The NVX-CoV2373 vaccine was efficacious in preventing Covid-19, with higher 
vaccine efficacy observed among HIV-negative participants. Most infections were 
caused by the B.1.351 variant. (Funded by Novavax and the Bill and Melinda Gates 
Foundation; ClinicalTrials.gov number, NCT04533399.)
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The coronavirus disease 2019 (Covid-19) pandemic, caused by the emergence of a novel severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), had resulted in more 
than 144 million documented cases and 3 million 
deaths worldwide as of April 23, 2021.1,2 Vaccina-
tion remains a cornerstone of control strategies. 
Current vaccines primarily target the SARS-
CoV-2 spike protein on the basis of the prototype 
Wuhan strain.3 The messenger RNA (mRNA) 
vaccines (BNT162b2 and mRNA-1273) have 
shown vaccine efficacy of 94 to 95%4,5 against 
Covid-19 of any severity, and corresponding vac-
cine efficacy for vector-based vaccines has been 
reported to be 70% for ChAdOx1 nCoV-19, 92% 
for Gam-COVID-Vac, and 67% for Ad26.COV2.S, 
with the Ad26.COV2.S vaccine measured against 
moderate-to-severe Covid-19.6-8
Among the Covid-19 vaccines under develop-
ment is a recombinant SARS-CoV-2 nanoparticle 
vaccine (NVX-CoV2373, Novavax). The vaccine is 
produced by engineering a baculovirus that con-
tains a gene encoding full-length SARS-CoV-2 
spike glycoprotein (prototype Wuhan-Hu-1 se-
quence) stabilized in the prefusion conforma-
tion. Cultures of cells obtained from the Spodoptera 
frugiperda moth are infected with recombinant 
baculovirus to express SARS-CoV-2 spike protein 
trimers, which are then extracted and chromato-
graphically purified. When formulated with poly-
sorbate 80 (PS 80), the purified trimers assemble 
into protein nanoparticles consisting of rosettes 
of spike trimers held together by hydrophobic 
interactions with a PS 80 micellar core. The 
nanoparticles are then further coformulated with 
the saponin-based adjuvant Matrix-M1.9,10 In an 
ongoing randomized, placebo-controlled, phase 
1–2 trial involving healthy adults, the NVX-CoV2373 
vaccine, administered in a two-dose regimen 21 
days apart, had an acceptable safety profile and 
was associated with a strong antigen-specific 
polyfunctional CD4+ T-cell response and induced 
a neutralizing-antibody level that was four times 
the level in convalescent serum obtained from 
patients with predominantly moderate-to-severe 
Covid-19.11
Recent reports from the United Kingdom, 
Brazil, and South Africa on the emergence of the 
B.1.1.7, P1, and B.1.351 (N501Y.V2) variants, re-
spectively, confirm the acquisition of mutations 
in key antigenic sites in the receptor-binding 
domain and N-terminal domain of the spike 
protein.12-17 These antigenic changes may render 
naturally acquired or vaccine-derived immunity 
to prototype-like virus less effective against sub-
sequent infection with variant viruses.13,17-19 Here, 
we describe early findings on the primary effi-
cacy end point and preliminary safety of a ran-
domized, observer-blinded, placebo-controlled, 
phase 2a–b trial of NVX-CoV2373 in South Africa 
during a period of predominant circulation of 
the B.1.351 variant virus.
Me thods
Trial Design and Participants
From August 17, 2020, through November 25, 
2020, we enrolled participants at 16 sites in 
South Africa. The trial was designed to provide 
a preliminary evaluation of vaccine safety and 
efficacy during ongoing pandemic transmission 
of SARS-CoV-2. Participants were healthy adults 
between the ages of 18 and 84 years without hu-
man immunodeficiency virus (HIV) infection or 
a subgroup of adults between the ages of 18 and 
64 years with HIV infection whose condition 
was medically stable. Baseline IgG antibodies 
against the spike protein (anti-spike IgG anti-
bodies) were measured at study entry to help 
determine baseline SARS-CoV-2 serostatus for 
the analysis of vaccine efficacy. As a safety mea-
sure, enrollment was staggered into stage 1 (de-
fined by the first third of targeted enrollment) 
and stage 2 (the remainder of enrollment) for 
both HIV-negative and HIV-positive participants. 
Progression from stage 1 to stage 2 in each 
group required a favorable review of safety data 
through day 7 from the previous stage against 
prespecified rules that would trigger a pause in 
vaccine administration. (Details regarding the 
participants in each stage are provided in Table 
S1 in the Supplementary Appendix, available with 
the full text of this article at NEJM.org.)
Key exclusion criteria were pregnancy, long-
term receipt of immunosuppressive therapy, auto-
immune or immunodeficiency disease except for 
medically stable HIV infection, a history of con-
firmed or suspected Covid-19, and SARS-CoV-2 
infection as confirmed on a nucleic acid ampli-
fication test (NAAT) performed as part of screen-
ing within 5 days before anticipated initial ad-
ministration of the vaccine or placebo. All the 
participants provided written informed consent 
before enrollment. Additional details regarding 
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the trial design, conduct, oversight, and analyses 
are provided in the Supplementary Appendix and 
the protocol (which includes the statistical analy-
sis plan), available at NEJM.org.
Oversight
The NVX-CoV2373 vaccine was developed by 
Novavax, which sponsored the trial and was re-
sponsible for the overall design (with input from 
the lead investigator), site selection, monitoring, 
and analysis. Trial investigators were responsible 
for data collection. The protocol was approved 
by the South African Health Products Regulatory 
Authority and by the institutional review board 
at each trial center. Oversight of safety, which 
included monitoring for specific vaccination-
pause rules, was performed by an independent 
safety monitoring committee.
The first author wrote the first draft of the 
manuscript with assistance from a medical writer 
who is an author and an employee of Novavax. 
All the authors made the decision to submit the 
manuscript for publication and vouch for the ac-
curacy and completeness of the data and for the 
fidelity of the trial to the protocol.
Trial Procedures
Participants were randomly assigned in a 1:1 ratio 
to receive two intramuscular injections, 21 days 
apart, of either NVX-CoV2373 (5 μg of recombi-
nant spike protein with 50 μg of Matrix-M1 adju-
vant) or saline placebo (injection volume, 0.5 ml), 
administered by staff members who were aware 
of trial-group assignments but were not other-
wise involved with other trial procedures or data 
collection. All other staff members and trial 
participants remained unaware of trial-group 
assignments. Participants were scheduled for in-
person follow-up visits on days 7, 21, and 35 and 
at 3 months and 6 months to collect vital signs, 
review any adverse events, discuss changes in 
concomitant medications, and obtain blood sam-
ples for immunogenicity analyses. A follow-up 
telephone visit was scheduled for 12 months af-
ter vaccination.
Safety Assessments
The primary safety end points were the occur-
rence of all unsolicited adverse events, including 
those that were medically attended, serious, or of 
special interest, through day 35 (Tables S2 and 
S3) and solicited local and systemic adverse events 
that were evaluated by means of a reactogenicity 
diary for 7 days after each vaccination (Tables S4 
and S5). Safety follow-up was ongoing through 
month 12.
Efficacy Assessments
The primary efficacy end point was confirmed 
symptomatic Covid-19 that was categorized as 
mild, moderate, or severe (hereafter called symp-
tomatic Covid-19) and that occurred within 7 days 
after receipt of the second injection (i.e., after 
day 28) (Table S6). Starting on day 8 and con-
tinuing through 12 months, we performed active 
surveillance (telephone calls every 2 weeks from 
trial sites to participants) and passive surveil-
lance (telephone contact at any time from partici-
pants to trial sites) for symptoms of suspected 
Covid-19 (Table S7 and Fig. S1). A new onset of 
suspected symptoms of Covid-19 triggered ini-
tial in-person and follow-up surveillance visits to 
perform clinical assessments (vital signs, includ-
ing pulse oximetry, and a lung examination) and 
for collection of nasal swabs (Fig. S2). In addi-
tion, suspected Covid-19 symptoms were also as-
sessed and nasal swabs collected at all scheduled 
trial visits. Nasal-swab samples were tested for 
the presence of SARS-CoV-2 by NAAT with the 
use of the BD MAX system (Becton Dickinson). 
We used the InFLUenza Patient-Reported Out-
come (FLU-PRO) questionnaire to comprehen-
sively assess symptoms for the first 10 days of a 
suspected episode of Covid-19.
Whole-Genome Sequencing
In a blinded fashion, we performed post hoc 
whole-genome sequencing of nasal samples ob-
tained from all the participants who had symp-
tomatic Covid-19. Details regarding the whole-
genome sequencing methods and phylogenetic 
analysis are provided in Fig. S3.
Statistical Analysis
The safety analysis population included all the 
participants who had received at least one injec-
tion of NVX-CoV2373 or placebo; regardless of 
group assignment, participants were evaluated 
according to the intervention they had actually 
received. Safety analyses were presented as num-
bers and percentages of participants who had 
solicited local and systemic adverse events 
through day 7 after each vaccination and who 
had unsolicited adverse events through day 35.
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We performed a per-protocol efficacy analysis 
in the population of participants who had been 
seronegative for SARS-CoV-2 at baseline and who 
had received both injections of NVX-CoV2373 or 
placebo as assigned, had no evidence of SARS-
CoV-2 infection (by NAAT or anti-spike IgG 
analysis) within 7 days after the second injection 
(i.e., before day 28), and had no major protocol 
deviations affecting the primary efficacy out-
come. A second per-protocol efficacy analysis 
population was defined in a similar fashion ex-
cept that participants who were seropositive for 
SARS-CoV-2 at baseline could be included.
Vaccine efficacy (calculated as a percentage) 
was defined as (1–RR)×100, where RR is the rela-
tive risk of Covid-19 illness in the vaccine group 
as compared with the placebo group. The official, 
event-driven efficacy analysis targeted a mini-
mum number of 23 end points (range, 23 to 50) 
to provide approximately 90% power to detect 
vaccine efficacy of 80% on the basis of an inci-
dence of symptomatic Covid-19 of 2 to 6% in the 
placebo group. This analysis was performed at 
an overall one-sided type I error rate of 0.025 for 
the single primary efficacy end point. The rela-
tive risk and its confidence interval were estimat-
ed with the use of Poisson regression with ro-
bust error variance. Hypothesis testing of the 
primary efficacy end point was performed against 
the null hypothesis of vaccine efficacy of 0%. 
The success criterion required rejection of the null 




Of the 6324 participants who underwent screen-
ing, 4387 received at least one injection of NVX-
CoV2373 or placebo (2199 in the vaccine group 
and 2188 in the placebo group); 4332 partici-
pants received both injections (Fig. 1).
Demographic and baseline characteristics were 
well balanced in the two groups (Table 1). The 
mean age of all participants was 32.0 years, and 
4.2% of the participants in each group were be-
tween the ages of 65 and 84 years. Approxi-
mately 57% of the participants were men, and 
most were Black African (95.3%). Twenty percent 
of the participants were obese, 5.6% had hyper-
tension, and 1.6% had type 2 diabetes. Approxi-
mately 30% of the participants were seropositive 
at baseline according to an evaluation of anti-
spike IgG antibodies (with a sensitivity of 94.7% 
and a specificity of 96.4% at a predefined anti-
spike IgG threshold). (Details regarding the anti-
spike IgG threshold determination are provided 
in the Supplementary Appendix.)
Safety
Preliminary safety data were available on all 
stage 1 participants, which included the first 
889 HIV-negative participants and the first 80 
HIV-positive participants who had completed 
safety follow-up through at least day 35 at the 
time of the cutoff date for the primary efficacy 
analysis (Table S8). Briefly, solicited local and 
systemic adverse events, which were predomi-
nantly mild to moderate and transient, were 
more common in the vaccine group than in the 
placebo group. After the first dose, the most 
frequently reported solicited local adverse event 
was injection-site pain (in 37% of the partici-
pants who were seronegative at baseline and 
39% of those who were seropositive in the vac-
cine group, and in 15% and 16% of the partici-
Figure 1 (facing page). Enrollment and Outcomes.
The full analysis set included all the participants who had 
undergone randomization and who had received at least 
one dose of the NVX-CoV2373 vaccine or placebo, re-
gardless of protocol violations or missing data; data were 
analyzed according to the assigned trial group. The safe-
ty analysis set included all the participants who had re-
ceived at least one dose of NVX-CoV2373 or placebo, 
with participants assessed according to the trial injection 
they actually received. Among the participants who were 
excluded from participating in the trial, approximately 
32% had positive results on testing for human immuno-
deficiency virus (HIV) at screening, 18% had a history 
of suspected or diagnosed severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) infection, 11% had 
an exclusionary chronic medical condition, 9% had an 
exclusionary high or low body-mass index, 7% could not 
provide informed consent, and 5% had acute or ongo-
ing illness. Among the participants who were excluded 
for other reasons, approximately 69% were otherwise 
eligible but had missed the time window for enrollment 
in a particular stage or cohort; in 23% of the participants, 
the reason for exclusion was not specified. The data-
cutoff date for the primary efficacy analysis was January 
8, 2021, which represented a median follow-up of 66 
days after the first dose and 45 days after the second 
dose. The data-cutoff date for the primary safety analy-
sis was January 25, 2021, which included safety data 
through 35 days after the first dose in all 968 stage 1 
participants (889 who were HIV-negative and 79 who 
were HIV-positive).
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pants, respectively, in the placebo group) (Table 
S9). The incidence of solicited local adverse 
events after the second dose was similar to that 
after the first dose, with a mean duration (gen-
erally <3 days) that was slightly longer after the 
second dose. Severe local adverse events were 
infrequent but occurred more often after the 
second dose among the seronegative participants 
in the vaccine group than in the placebo group 
(4% vs. 1%).
Among the vaccine recipients, the most com-
mon solicited systemic adverse events after the 
first dose and second dose were headache (20 to 
25%), muscle pain (17 to 20%), and fatigue (12 
to 16%). The mean duration of such events was 
slightly longer after the second dose but gener-
ally less than 3 days. Among the participants 
who were seronegative at baseline, grade 3 sys-
temic adverse events were infrequent but were 
more common in the vaccine group after the 
second dose (4%) than after the first dose (2%), 
although the incidence was similar to that in the 
4406 Underwent randomization
6324 Participants were assessed for eligibility
1918 Were excluded
1330 Did not meet inclusion criteria
450 Had other reasons
16 Had missing or unknown reason
76 Withdrew
21 Did not meet randomization criteria
23 Were lost to follow-up
2 Had adverse event
2206 Were assigned to receive NVX-CoV2373
2197 Received NVX-CoV2373 and were
included in the full analysis population
9 Did not receive NVX-CoV2373 because
of withdrawal from trial 
2199 Were included in the safety analysis
population
2200 Were assigned to receive placebo
2190 Received placebo and were included in
the full analysis population
10 Did not receive placebo because of
withdrawal from trial 






positivity before day 28
24 Did not receive both
doses






positivity before day 28
31 Did not receive both
doses
7 Had important protocol
deviations
24 Discontinued NVX-CoV2373
1 Had adverse event, not related to vaccine
13 Withdrew
6 Were lost to follow-up
1 Was withdrawn by physicians
2 Became pregnant 
1 Had other reason
31 Discontinued placebo
14 Withdrew
9 Were lost to follow-up
3 Became pregnant 
5 Had other reason
1357 Were included in per-protocol
efficacy analysis
1327 Were included in per-protocol
efficacy analysis
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placebo group (4%), particularly with respect to 
fatigue and headache (Tables S8 and S9). Reacto-
genicity was generally similar among seronega-
tive and seropositive vaccine recipients.
Medically attended adverse events (Table S10) 
and serious adverse events (Table S11) were in-
frequent but occurred more often in the vaccine 
group than in the placebo group (13 vs. 6 medi-
cally attended adverse events and 2 vs. 1 serious 
adverse events). There was no apparent cluster-
ing of specific adverse events according to inter-
vention group, preferred term, or system organ 
class. To date, no serious adverse events have 
been assessed by trial investigators as being re-
lated to the vaccine (Table S8). No prespecified 
vaccination-pause rules were triggered.
Efficacy
Among the 2684 participants who were sero-
negative at baseline (94% who were HIV-negative 
and 6% who were HIV-positive) and who could 
be evaluated in the analysis of the primary efficacy 
end point after day 28, symptomatic Covid-19 
was observed in 15 participants in the vaccine 
group and in 29 participants in the placebo 
group. These findings corresponded to a vaccine 
efficacy of 49.4% (95% confidence interval [CI], 
6.1 to 72.8), which met the criterion for efficacy 
in the primary phase 2b evaluation (Table 2 and 
Fig. 2A). All the cases of Covid-19 in the per-
protocol analysis were mild to moderate, except 
for one severe case in the placebo group.
Among the participants who were HIV-nega-









Mean — yr 31.9±12.9 32.2±13.0 32.0±13.0
Median — yr 28.0 28.0 28.0
Distribution — no. (%)
18–64 yr 2104 (95.7) 2094 (95.7) 4198 (95.7)
65–84 yr 92 (4.2) 92 (4.2) 184 (4.2)
Missing data 3 (0.1) 2 (0.1) 5 (0.1)
Sex — no. (%)
Male 1252 (56.9) 1266 (57.9) 2518 (57.4)
Female 947 (43.1) 922 (42.1) 1869 (42.6)
Race — no. (%)†
Black 2098 (95.4) 2082 (95.2) 4180 (95.3)
White 86 (3.9) 66 (3.0) 152 (3.5)
Other 40 (1.8) 49 (2.2) 89 (2.0)
Body-mass index‡
Mean 25.1±6.0 25.0±5.9 25.0±6.0
30 to 40 — no. (%) 451 (20.5) 440 (20.1) 891 (20.3)
Coexisting condition — no. (%)
Hypertension 125 (5.7) 119 (5.4) 244 (5.6)
Type 2 diabetes 31 (1.4) 39 (1.8) 70 (1.6)
Seropositivity for SARS-CoV-2 — no. (%)
Nucleic acid amplification test 63 (2.9) 63 (2.9) 126 (2.9)
Anti-spike immunoglobulin G assay 651 (29.6) 673 (30.8) 1324 (30.2)
*  Plus–minus values are means ±SD. The NVX-CoV2373 vaccine consists of 5 μg of recombinant spike protein with 50 
μg of Matrix-M1 adjuvant.
†  Race was reported by the participants.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
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tive (a subgroup of the primary efficacy end 
point), symptomatic Covid-19 was observed in 
11 participants in the vaccine group and in 27 
participants in the placebo group among those 
who were seronegative at baseline, which corre-
sponded to a vaccine efficacy of 60.1% (95% CI, 
19.9 to 80.1) (Table 2 and Fig. 2B); the corre-
sponding vaccine efficacy estimate was 52.2% 
(95% CI, −24.8 to 81.7) among those who were 
seropositive at baseline.
Among the participants who were HIV-posi-
tive and seronegative at baseline (another sub-
group of the primary efficacy end point), symp-
tomatic Covid-19 was observed in 4 of 76 
participants in the vaccine group and in 2 of 72 
participants in the placebo group. No cases were 
observed among the participants who were HIV-
positive and seropositive at baseline in either 
group (33 in the vaccine group and 30 in the 
placebo group).
Among the participants who were seronega-
tive at baseline, the 44 cases of symptomatic 
Covid-19 in the two groups occurred between 
November 23 and December 30, 2020. Of these 
participants, 41 (93%) had samples that were 
adequate for whole-genome sequencing; samples 
from 3 participants in the placebo group could 
not be sequenced. Of the 41 samples, the B.1.351 
variant was identified in 38 (93%), which mir-
rored the national incidence during the same 
period (Fig. 2D and Fig. S1). In a post hoc analy-
sis, vaccine efficacy against the B.1.351 variant 
was 51.0% (95% CI, −0.6 to 76.2) among the 
HIV-negative participants (11 in the vaccine 
group and 22 in the placebo group) and 43.0% 
(95% CI, −9.8 to 70.4) in the combined HIV-
negative and HIV-positive population (14 partici-
pants and 24 participants, respectively).
Notably, during the initial 60 days of follow-
up in the placebo group, the preliminary inci-
dence of Covid-19 that was observed among 
participants who were seronegative at baseline 
(5.3%; 95% CI, 4.3 to 6.6), which included 33 
mild and 47 moderate cases among 1516 par-
ticipants, was similar to the incidence among 
seropositive participants (5.2%; 95% CI, 3.6 to 
7.2), which included 14 mild and 21 moderate 
cases among 674 participants (Fig. 2C).
Discussion
We describe preliminary evidence of the efficacy 
of a two-dose regimen of NVX-CoV2373 nanopar-
ticle vaccine in preventing symptomatic Covid-19 
during predominant transmission of the B.1.351 
variant in South Africa.12,15 The vaccine fulfilled 
the primary objective by showing significant vac-
cine efficacy of 49.4% among participants who 
were seronegative for SARS-CoV-2 at baseline 
regardless of HIV serostatus. Among the 94% of 
participants without HIV infection, the vaccine 
efficacy was 60.1%. The trial was not powered to 
Table 2. Vaccine Efficacy against Symptomatic Covid-19 at Least 7 Days after the Second Dose (Day 28).*
Population and Baseline Anti-Spike 
IgG Serostatus
No. of 
Cases Vaccine Group Placebo Group
Vaccine Efficacy 
(95% CI)†
no./total no. % (95% CI) no./total no. % (95% CI) %
All participants
Seronegative at baseline: primary end 
point
44 15/1357 1.1 (0.6 to 1.8) 29/1327 2.2 (1.5 to 3.1) 49.4 (6.1 to 72.8)
Seropositive at baseline 19 6/500 1.2 (0.4 to 2.6) 13/514 2.5 (1.4 to 4.3) 52.6 (−23.8 to 81.8)
Any serostatus at baseline 63 21/1857 1.1 (0.7 to 1.7) 42/1841 2.3 (1.6 to 3.1) 50.4 (16.6 to 70.5)
HIV-negative participants
Seronegative at baseline 38 11/1281 0.9 (0.4 to 1.5) 27/1255 2.2 (1.4 to 3.1) 60.1 (19.9 to 80.1)
Seropositive at baseline 19 6/467 1.3 (0.5 to 2.8) 13/484 2.7 (1.4 to 4.5) 52.2 (−24.8 to 81.7)
Any serostatus at baseline 57 17/1748 1.0 (0.6 to 1.6) 40/1739 2.3 (1.6 to 3.1) 57.7 (25.7 to 75.9)
*  Symptomatic coronavirus disease 2019 (Covid-19) was confirmed by means of nucleic acid amplification testing. Data are listed for the pri-
mary per-protocol analysis population (which included participants who were seronegative for SARS-CoV-2 at baseline) and the secondary 
per-protocol analysis population (which included all the participants regardless of serostatus at baseline). HIV denotes human immunodefi-
ciency virus.
†  The 95% confidence interval for vaccine efficacy was calculated by means of the exact Clopper–Pearson method.
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detect efficacy in the small population of par-
ticipants with HIV infection. Preliminary safety 
data continued to indicate an acceptable safety 
and reactogenicity profile.11
In this placebo-controlled vaccine trial, we 
found that previous infection with first-wave 
prototype-like, pre-B.1.351 viruses did not ap-
pear to reduce the risk of Covid-19 due to subse-
quent infection with B.1.351 variants among 
placebo recipients during the initial 2 months of 
follow-up. This finding is preliminary and may 
have public health implications for pandemic 
modeling, control strategies, and vaccine devel-
opment and deployment efforts. It is also consis-
tent with the lack of incremental benefit con-
ferred by preexisting immunity in vaccine recipients 
as evidenced in our trial by consistent levels of 
efficacy regardless of baseline serostatus for 
Figure 2. Kaplan–Meier Analysis of NVX-CoV2373 Efficacy against Symptomatic Covid-19 and Timing of Trial Data Accrual.
Shown is the cumulative incidence of symptomatic coronavirus disease 2019 (Covid-19) among the trial participants who were seronega-
tive for SARS-CoV-2 at baseline 7 days after the administration of the second dose of NVX-CoV2373 vaccine or placebo (i.e., day 28) in 
the per-protocol analysis set, regardless of HIV serostatus (primary efficacy end point) (Panel A) and among the participants who were 
HIV-negative at baseline (a subgroup of the primary efficacy end point) (Panel B). Also shown is the incidence among participants in the 
placebo group who were seronegative for SARS-CoV-2 at baseline as compared with those who were seropositive at baseline in the full 
analysis set starting on day 0 (Panel C). The full analysis set included all the participants who had undergone randomization and who 
had received at least one dose of NVX-CoV2373 or placebo, regardless of protocol violations or missing data. In Panels A, B, and C, the 
insets show the data on an expanded y axis. The period of accrual of trial data for the per-protocol analysis of the efficacy end points is 
indicated by the dashed-line box, relative to the background circulation of the B.1.351 variant (noted here as clade 20H/501Y.V2) in South 
Africa (Panel D). Data regarding viral circulation are shown according to phylogenetic clade (19A, 20B, etc.) and percent circulation of 
each clade according to calendar time. Data have been adapted from Nextstrain.org and are freely available under the terms of the GNU 
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SARS-CoV-2. Although these findings require 
further confirmation, our observations suggest 
that vaccination with prototype-sequenced NVX-
CoV2373 conferred a degree of cross-protection 
against an immunologic escape variant.
Factors that may have created a milieu that 
was favorable to the emergence of the B.1.351 
variant in South Africa include intense transmis-
sion during the first wave of infection, high levels 
of resulting immunity to prototype variants (as 
observed in our trial and corroborated in sero-
surveys20), and an ongoing high force of infec-
tion in advance of the second wave. The B.1.351 
variant is reported to have emerged in the East-
ern Cape Province of the country in October 
2020 and rapidly spread to become the dominant 
circulating strain throughout the country during 
November and December 2020,15 a period that 
coincided with the surge of second-wave trans-
mission nationally. In our trial, which was con-
ducted at sites that were dispersed across the 
country, we observed 44 cases of symptomatic 
Covid-19 between November 23 and December 
30, 2020. Sequencing of nasal samples from 
participants with confirmed Covid-19 showed a 
pattern consistent with national molecular epi-
demiologic features.
The B.1.351 variant is characterized by three 
deleterious mutations at key antigenic sites in 
the receptor-binding domain, including N501Y, 
K417N, and E484K, with the latter two having 
particular functional effect.13,15,17,18 The N501Y 
mutant is known to increase binding affinity of 
the spike protein to the human angiotensin-
converting enzyme 2 receptor21 and has been re-
ported to increase transmissibility of the B.1.1.7 
variant that was first identified in the United 
Kingdom.16 The E484K mutant has been reported 
to abolish or substantially reduce neutralization 
by multiple potent monoclonal antibodies and 
polyclonal convalescent serum on both wild-type 
and pseudovirus neutralization assays.12,13,17,18,22 In 
addition, postvaccination serum obtained from 
volunteers who had received either of the two 
mRNA vaccines that are currently being admin-
istered had reductions by a factor of 6.5 to 8.6 in 
neutralizing capacity to the B.1.351 variant rela-
tive to prototype virus on pseudovirus neutral-
ization assays17; however, the effect of this find-
ing on clinical efficacy has not been assessed. 
Wild-type and pseudovirus neutralization assays 
assessing the effect of the B.1.351 variant on the 
neutralizing capacity of NVX-CoV2373 vaccine-
elicited antibodies are in progress. Nevertheless, 
our data provide clinical evidence of cross-pro-
tection against antigenically drifted viruses. In 
the interim analysis of our phase 3 trial being 
conducted in the United Kingdom, relatively high 
levels of efficacy were observed against both the 
matched prototype-like, prevariant strains (vac-
cine efficacy, 96%) and the B.1.1.7 variant (vaccine 
efficacy, 86%).23 The high vaccine efficacy against 
the B.1.1.7 variant is consistent with the ex-
pected limited effect of the characteristic N501Y 
mutant (without a concomitant E484K mutant) 
on in vitro neutralization capacity of convales-
cent serum derived from prototype-like virus 
infections.13,17
Investigators have recently reported efficacy 
results of two other trials that have been par-
tially or wholly conducted in South Africa and 
that are contemporaneous with circulation of 
the B.1.351 variant. In a large, multinational, 
phase 3 trial evaluating the efficacy of a single 
dose of the Ad26.COV2.S vaccine (Johnson & 
Johnson/Janssen), efficacy against moderate-to-
severe Covid-19 among 6576 participants in South 
Africa was 52% at 14 days and 64% at 28 days 
after the first dose, with 95% of cases report-
edly due to the B.1.351 variant. Vaccine efficacy 
against all-severity Covid-19 specific to the 
B.1.351 variant has not yet been reported, preclud-
ing a direct comparison with other vaccines.8,24 
In the second trial, the ChAdOx1 nCoV-19 vac-
cine (AstraZeneca) was evaluated in a phase 2 
trial involving 2026 participants in South Africa 
in a population resembling that in our trial. 
Cases of Covid-19 among vaccine recipients were 
predominantly mild to moderate, with a reported 
overall vaccine efficacy of 22% (95% CI, −50 to 
60) and an efficacy of 10% (95% CI, −77 to 55) 
against the B.1.351 variant, with the B.1.351 
variant making up 95% of cases.25
Our trial has several limitations. The efficacy 
results are preliminary, with a median follow-up 
of 66 days after the first dose and 45 days after 
the second dose, and are limited in scope to the 
primary end point and subgroups of the primary 
end point, along with a post hoc analysis of 
B.1.351 variant sequencing data. Thus, caution is 
warranted in the interpretation of our results on 
the breadth of natural immunity and vaccine ef-
fects in the HIV-positive cohort, which repre-
sents a relatively small fraction of the trial popu-
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lation. At the time of analysis, trial investigators 
had captured almost exclusively mild-to-moder-
ate Covid-19 end points in a predominantly young, 
healthy population; consequently, we have not 
as yet been able to report on vaccine efficacy 
against severe Covid-19. Most large trials of vac-
cine efficacy against Covid-19 have reported nota-
bly higher vaccine efficacy against severe disease 
than against mild-to-moderate disease.4-7 Addi-
tional follow-up may shed light on whether 
naturally acquired immunity to prototype-like 
virus alters the severity of infection caused by 
variant viruses.
We have found that a prototype-sequenced 
NVX-CoV2373 vaccine was efficacious and induced 
notable cross-protection during a pandemic with 
a dominant circulation of the B.1.351 variant.
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